Christopher Locher, PhD is a biotechnology entrepreneur and executive with more than 20 years of experience in working relationships with biopharma partners and investors. He is the CEO of Versatope Therapeutics, a preclinical-stage Massachusetts-based company focused on the development of a universal influenza vaccine and supporting biopharma industry partner programs. He previously led projects for infectious diseases at Vertex Pharmaceuticals, Inc. in Boston, inflammatory diseases at Opsona Therapeutics, Ltd. in Ireland and malaria and alphaviruses vaccine development programs at Maxygen, Inc. in California. He completed postdoctoral training at the University of California, San Francisco and was a Fulbright Hayes Research Fellow at the Institute of Tropical Medicine in Antwerp, Belgium. He received his PhD in Tropical Medicine and BA in Biol Sci from the University of Hawai`i at Mānoa and Hilo, respectively.